TNFRSF17 and plasma cell myeloma: Targeting BCMA for multiple myeloma is a second CAR T cell therapy that has gained a lot of traction in recent years,132,133 with emerging single-cell genomics studies starting to better define determinants of response and resistance to BCMA CAR.